Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPXFree Report) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, Wedbush reiterated an outperform rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Friday, March 22nd.

View Our Latest Stock Report on Compass Therapeutics

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $1.62 on Tuesday. The business has a 50-day simple moving average of $1.77 and a 200 day simple moving average of $1.68. Compass Therapeutics has a one year low of $1.15 and a one year high of $3.62. The firm has a market capitalization of $222.21 million, a price-to-earnings ratio of -4.75 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPXGet Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). On average, sell-side analysts expect that Compass Therapeutics will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Compass Therapeutics in the third quarter valued at about $76,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Compass Therapeutics by 15.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 132,792 shares of the company’s stock valued at $262,000 after buying an additional 17,746 shares during the last quarter. Pale Fire Capital SE bought a new position in shares of Compass Therapeutics during the 3rd quarter worth approximately $89,000. Blackstone Inc. lifted its position in shares of Compass Therapeutics by 3.1% during the 3rd quarter. Blackstone Inc. now owns 6,189,551 shares of the company’s stock worth $12,193,000 after buying an additional 188,811 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Compass Therapeutics by 2.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 6,380,000 shares of the company’s stock worth $12,569,000 after buying an additional 130,000 shares during the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Featured Stories

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.